Pardes Biosciences

Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world’s most pressing public health challenges. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery.
 
The company’s lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections. PBI-0451 is designed to inhibit the coronavirus main protease, an essential protein for SARS-CoV-2. This protease is highly similar across all coronaviruses, including emerging coronavirus variants. Pardes Biosciences is headquartered in Carlsbad CA.

Our Investors

Pardes Biosciences is backed by a world class team of investors with deep expertise in biopharmaceutical research and development, digital health, diagnostics, and care delivery transformation.  These investors share a goal of supporting the growth of new companies that have the potential to transform their respective industries and improve the health of patients across the globe.

Current Job Openings

Development

Regulatory

Translational Science

Director, DMPK
United States
Director, Toxicology
United States

Technical Operations

CMC Development